



Alseres Pharmaceuticals, Inc. Reports 2008 Results

HOPKINTON, Mass., March 26, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Alseres Pharmaceuticals, Inc. (Nasdaq: ALSE) today announced that they will host a conference call on Wednesday, April 1st at 9:00am EDT to review 2008 results.

(Logo: <http://www.newscom.com/cgi-bin/prnh/20080813/NEW056LOGO>)

To access the conference call, please dial 1-877-856-1968 for domestic and 1-719-325-4770 for international calls. The code for this conference call is 2264513. Please dial in 5 to 10 minutes prior to the scheduled start time. A replay of the call will be posted on the Investor Relations section of our website, www.alseres.com, within 48 hours following the conference call and will be available through Wednesday, April 15th, 2009.

About Alseres Pharmaceuticals, Inc.

Alseres Pharmaceuticals, Inc. (ALSE) is engaged in the development of therapeutic and diagnostic products primarily for disorders in the central nervous system (CNS). The Company maintains a world-class intellectual property position in the field of regenerative therapeutics. The Company's energy and focus is reflected in several important initiatives. Cethrin, a recombinant-protein-based drug designed to promote nerve repair after acute spinal cord injury, demonstrated positive interim results in a Phase I/IIa clinical trial. The Company's research and pre-clinical programs include, Inosine for the treatment of spinal cord injury and stroke, Oncomodulin for the treatment of ocular injury and disease and research programs directed at a number of regenerative therapies including bone repair. The Company has a molecular imaging development program targeting diagnosis of Parkinson's disease and potentially dementia. The Company's lead molecular imaging product candidate is Altropane which is in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes including Parkinson's Disease.

Alseres, Cethrin and Altropane are registered trademarks of Alseres Pharmaceuticals, Inc.

Contact:

Kenneth L. Rice 508-497-2360 x226
Alseres Pharmaceuticals, Inc.
krice@alseres.com

SOURCE Alseres Pharmaceuticals, Inc.

<http://www.alseres.com>

Copyright (C) 2009 PR Newswire. All rights reserved